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REGULAR ARTICLE
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Key Points
• In this cohort of
patients with suspected
HIT, plasma sGPVI lev-
els were significantly
higher in patients with
major bleeding than
those without.
• sGPVI may be marker
of elevated bleeding
risk in patients with
suspected HIT.
We have shown that patients with suspected heparin-induced thrombocytopenia (HIT)
have a high incidence of major bleeding. Recent studies have implicated elevated soluble
glycoprotein VI (sGPVI) levels as a potential risk factor for bleeding. We sought to
determine if elevated sGPVI plasma levels are associated with major bleeding events in
patients with suspected HIT. We used a cohort of 310 hospitalized adult patients with
suspected HIT who had a blood sample collected at the time HIT was suspected. Plasma
sGPVI levels were measured by using enzyme-linked immunosorbent assay. Patients
were excluded who had received a platelet transfusion within 1 day of sample collection
because of the high levels of sGPVI in platelet concentrates. We assessed the association
of sGPVI (high vs low) with International Society on Thrombosis and Haemostasis major
bleeding events by multivariable logistic regression, adjusting for other known risk
factors for bleeding. Fifty-four patients were excluded due to recent platelet transfusion,
leaving 256 patients for analysis. Eighty-nine (34.8%) patients had a major bleeding
event. Median sGPVI levels were significantly elevated in patients with major bleeding
events compared with those without major bleeding events (49.09 vs 31.93 ng/mL;
P , .001). An sGPVI level .43 ng/mL was independently associated with major bleeding
after adjustment for critical illness, sepsis, cardiopulmonary bypass surgery, and degree
of thrombocytopenia (adjusted odds ratio, 2.81; 95% confidence interval, 1.51-5.23). Our
findings suggest that sGPVI is associated with major bleeding in hospitalized patients
with suspected HIT. sGPVI may be a novel biomarker to predict bleeding risk in patients
with suspected HIT.
Introduction
Clinical practice guidelines suggest that patients with suspected heparin-induced thrombocytopenia
(HIT) and an intermediate to high probability 4Ts score be treated with a nonheparin anticoagulant
while awaiting HIT confirmatory laboratory test results.1 Although HIT is a prothrombotic condition,
patients with suspected HIT have a high incidence of major bleeding.2,3 Thus, the decision to initiate
empiric alternative anticoagulation (often at therapeutic-intensity) in patients with suspected HIT is
a challenging one. Clinicians must weigh the risk of bleeding vs the risk of thrombosis for the individual
patient. Bleeding risk assessment is particularly difficult in the absence of well-validated bleeding
prediction models for hospitalized patients. Studies have identified some risk factors based on routine
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clinical laboratory findings, but bleeding risk scores for inpatients
have not been widely adopted in clinical practice nor have they
been applied to patients with suspected HIT.4 Identifying addi-
tional biomarkers to predict bleeding risk is important to help
guide management and may also shed light on mechanisms of
bleeding.
Glycoprotein VI (GPVI) is a platelet-specific surface marker shed
from the platelet surface during platelet activation or other
causes.5,6 Soluble GPVI (sGPVI) can be measured in the plasma
by using an enzyme-linked immunosorbent assay and typi-
cally exhibits little variation among healthy subjects, ranging
from 11 to 24 ng/mL.6 Increased sGPVI levels are linked to
adverse outcomes in sepsis, thermal injury patients, and trauma.7
Elevated sGPVI levels before implantation of a left ventricular
assist device have been found to be associated with bleeding
events.8,9
The goal of the present study was to determine if sGPVI levels were
associated with bleeding outcomes in a cohort of patients with




This study used a previously described cohort of 310 hospitalized
adult patients with suspected HIT recruited from 2 hospitals, the
Hospital of the University of Pennsylvania and Penn Presbyterian
Medical Center.10 The ultimate determination of cases as “HIT
positive” or “HIT negative” was made by the consensus of an
expert panel based on clinical information and HIT laboratory
testing as described in Pishko et al.10 The original study was
approved by the University of Pennsylvania institutional review
board. All patients provided written informed consent for the
original study.
sGPVI measurement
All patients had a citrated plasma sample collected at the time HIT
was suspected. Plasma sGPVI levels were measured by enzyme-
linked immunosorbent assay of platelet-depleted plasma in dupli-
cate, and the average result was used for analysis.11 Patients’
transfused platelets within 1 day of sample collection were excluded
because of the potential presence of high levels of sGPVI in stored
platelet concentrates.12
Clinical and demographic variables
Clinical and demographic variables were extracted retrospectively
from the electronic health record, including platelet count on day of
sGPVI specimen collection, age, race, hospitalization in a critical
care unit, primary team caring for the patient (medical or surgical),
and surgery before specimen collection. We used International
Classification of Diseases, Ninth Revision, codes during the
patient’s admission to identify the presence or absence of sepsis
using the codes 038 (septicemia), 995.91 (sepsis), 995.92 (severe
sepsis), or 785.52 (septic shock).13
Outcomes
The study’s primary outcome was major bleeding according to
International Society of Thrombosis and Haemostasis (ISTH)
criteria, which includes fatal bleeding, hemorrhage occurring at
a critical area or organ (intracranial, intraspinal, intraocular,
retroperitoneal, intra-articular, pericardial, or intramuscular with
compartment syndrome), or bleeding causing a drop in hemoglo-
bin (Hb) of $2 g/dL, or leading to transfusion of 2 or more units
of whole blood or packed red blood cells (pRBCs).14 This
definition was modified to limit the 2 g/dL drop in Hb or 2-unit
pRBC transfusion to have occurred within a 24-hour period so
as to avoid the gradual reductions in Hb that can occur in
hospitalized patients. We assessed for the primary outcome from
time of sGPVI sample collection to hospital discharge or death.
Patients could only have 1 bleeding event, and their bleeding
event was classified according to the highest severity of ISTH
criteria fulfilled. For example, if a patient had a critical organ
and fatal bleed, the patient was categorized as having a fatal
bleed only. Secondary outcomes included the development
of arterial/venous thrombosis (confirmed by imaging) following
sGPVI sample collection until hospital discharge or death and
mortality at 30 days.
Statistical analysis
In patients with and without bleeding events, categorical
variables and continuous variables were compared between
patients with and without bleeding events by using a Wilcoxon
rank sum test (continuous variables) and a x2 test (categorical
variables). Among all patients in the cohort, we assessed for
associations with sGPVI levels as a continuous variable and
binary demographic/clinical variables (age [$65 or ,65 years],
sex, race [white vs non-white], HIT positivity, and sepsis) using
the Wilcoxon rank sum test. Missing values were not imputed.
We then performed receiver-operating curve (ROC) analysis
for sGPVI levels as a predictor of major bleeding events and
selected a dichotomous cut-point for sGPVI that maximized the
associated Youden’s index.15 Univariate logistic regression was
used to assess the association of sGPVI (high vs low) and other
clinical and demographic variables with the binary outcome of
bleeding event (yes/no). Variables from the univariate analysis
with P , .2 and interactions between these variables were
included in the full multivariable model of the association of
sGPVI and bleeding outcomes. We also built univariate logistic
regression models to assess the association of sGPVI levels
(high vs low) with the secondary outcomes of thrombosis and
30-day mortality.
All results are presented with 95% confidence intervals (CIs), and
P , .05 was considered statistically significant. Statistical analyses
were performed by using Stata version 14.0 (Stata Corp, College




Of the 310 patients in the original cohort, 54 (17.4%) were
excluded because they received a platelet transfusion within
24 hours of sample collection (Figure 1). Among the remaining
256 patients, 89 (34.8%) had an ISTH major bleeding event
during the time from sample collection to hospital discharge or
death. The majority (76.4% [68 of 89]) fulfilled criteria for major
bleeding due to need for 2 units of pRBCs or a 2 g/dL decrease
in Hb within a 24-hour period; 18.0% (16 of 89) of patients had
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a critical organ bleed, and 5.6% (5 of 89) had a fatal bleeding
event. The time from sGPVI sample collection to first major
bleeding event ranged from 0 to 28 days (median, 3 days).
Demographic and clinical characteristics of patients with and
without major bleeding are listed in Table 1. There was no
significant difference in the percentage of HIT-positive patients
among those with and without major bleeding (16.9% vs 13.8%;
P 5 .51). The majority of patients who had a major bleeding
event (74.2%) were hospitalized in the intensive care unit (ICU).
Patients with a major bleeding event were more likely to be on
a surgical service than those without a major bleeding event
(62.9% vs 47.9%; P 5 .02) and more likely to have sepsis during
their hospital stay (41.6% vs 19.8%; P , .001). Patients with
major bleeding had a lower median platelet count on the day of
sGPVI blood draw than patients without major bleeding events
(54.5 3 109/L vs 79 3 109/L; P 5 .004).
sGPVI levels in the study cohort
In the cohort, sGPVI levels ranged from 7.0 to 97.7 ng/mL, with
a median of 35.8 ng/mL. sGPVI levels did not vary significantly by
gender (P5 .81), age ($65 or,65 years) (P5 .91), or race (white
vs non-white) (P 5 .47). Median sGPVI levels were higher in
patients with sepsis than those without sepsis (46.5 [interquartile
range (IQR), 15.5-86.3] ng/mL vs 32.1 [IQR, 13.3-70.9] ng/mL;
P 5 .001). Median sGPVI levels were also significantly higher in
patients admitted to the ICU vs the wards (41.7 [IQR, 25.9-56.4]
ng/mL vs 31.9 [IQR, 20.6-43.1] ng/mL; P 5 .0002). There was no
significant difference in sGPVI levels in HIT-positive vs HIT-negative
patients (P 5 .10).
Association of sGPVI levels and bleeding outcomes
Median sGPVI levels were significantly elevated in patients with
major bleeding events compared with those without (49.1 [IQR,
28.5-64.5] ng/mL vs 31.9 [IQR, 21.2-43.1] ng/mL; P , .001)
(Figure 2). ROC analysis of sGPVI levels for predicting bleeding
events revealed an area under the curve of 0.69 (95% CI, 0.62-
0.76) (supplemental Figure 1). The cut-point that maximized
Youden’s index was 43.4 ng/mL. We thus defined sGPVIlow
as ,43 ng/mL and sGPVIhigh as $43 ng/mL. Other clinical and
demographic variables associated with a major bleeding event
were admission to the ICU, cardiopulmonary bypass surgery,
sepsis, and platelet count (supplemental Table 1). In the final
multivariable model, after adjustment for ICU status, sepsis,
cardiopulmonary bypass, and platelet count, sGPVIhigh remained
independently associated with major bleeding with an odds ratio
(OR) of 2.81 (95% CI, 1.51-5.23) (Table 2).
Association of sGPVI with thrombosis and mortality
Thirty-seven (14.45%) of 256 patients had a venous and/or
arterial thrombosis after sGPVI blood collection. sGPVIhigh was
not significantly associated with the development of venous
and/or arterial thrombosis after sGPVI sample collection (OR,
1.71; 95% CI, 0.85-3.45; P 5 .13). Sixteen (6.25%) patients
were lost to follow-up at 30 days. Among the remaining 240
patients, 25% were deceased. sGPVIhigh was associated with
increased 30-day mortality (OR, 2.14; 95% CI, 1.18-3.87).
Discussion
We found that plasma sGPVI levels were significantly higher in
patients with suspected HIT who had a major bleeding event
compared with patients with suspected HIT who did not have
a bleeding event. sGPVIhigh remained a significant predictor of
bleeding events when adjusted for the presence of sepsis,
hospitalization in the ICU, cardiopulmonary bypass, and degree
of thrombocytopenia. sGPVIhigh was also found to be signif-
icantly associated with 30-day mortality.
Our results are consistent with the findings of Muthiah et al,8 who
reported that mean sGPVI levels before left ventricular assist
device implantation were higher in patients with bleeding events
vs those without bleeding events (86 6 52 vs 52 6 19 ng/mL;
P 5 .008). A proposed mechanism in patients with cardiac
devices is that shear forces lead to excessive shedding of the
receptor and platelet dysfunction.8 In patients without such
devices, other disease processes such as sepsis may lead to
pathologic platelet activation and fibrin deposition, which in turn
causes inappropriate shedding of sGPVI and platelet dysfunction.5
310 patients with Suspected HIT
54 patients excluded due to
receiving platelet transfusion =1 day
prior to sGPVI blood draw
256 patients assessed for bleeding













Figure 1. Study cohort selection flowchart. Study
design and cohort allocation are shown.
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The current study found significantly higher sGPVI levels in patients
with sepsis vs those without sepsis. This aligns with previous
research by Montague et al,7 which likewise reported the associ-
ation of higher sGPVI levels in patients who experienced a thermal
injury and developed sepsis.
In our analysis of secondary outcomes, we found a significant
association between sGPVIhigh levels and 30-day mortality.
Montague et al7 also observed an association between elevated
sGPVI and 28-day mortality in ICU patients and patients with
thermal injury. Notably, in our study, we used a higher sGPVI
cutoff ($43 ng/mL) than Montague et al (.22.3 ng/mL), who
based their cutoff on levels in healthy control subjects. We
selected our sGPVI cutoff based on ROC analysis for prediction
of bleeding. sGPVI as a predictor of mortality requires further
study in a large cohort of patients to determine the ideal cutoff for
prognostication of this outcome.
A limitation of our study includes the retrospective nature of the
data collection. Although we used a standardized definition of
major bleeding, other causes of a 2 g/dL Hb drop or the need
for a 2-unit pRBC transfusion (eg, hemolysis/dilution) can be
difficult to ascertain from chart review. Furthermore, we chose
the time of sGPVI blood draw as the starting point for our
observation period. We did not record whether patients had
active bleeding before the sGPVI blood draw; thus, it is possible
that some patients may have experienced major bleeding before
this time point. In addition, the time period required after platelet
transfusion for sGPVI levels to return to baseline is not known.
We excluded patients receiving platelet transfusions within
24 hours, but it is not known if transfusions at 48 or 72 hours
could also affect results. Further prospective analyses with serial
measurements of sGPVI in individual patients are required to
establish sGPVI as a predictor of major bleeding rather than
a marker of ongoing or recent bleeding.
Despite these limitations, the current study supports previous
literature that elevated sGPVI levels may predict bleeding risk.8
A biomarker for bleeding risk in patients with suspected HIT
could prove useful for clinicians in weighing the risks and
benefits of empiric anticoagulation. For example, among patients
with suspected HIT and an intermediate-probability 4Ts score,
the American Society of Hematology clinical practice guidelines
on HIT suggests treatment with a nonheparin anticoagulant at
prophylactic-intensity if the patient is judged to be at high
bleeding risk and at therapeutic-intensity if the patient is deemed
not to be at elevated risk of bleeding.1 This recommendation is
challenging to implement in practice owing to a lack of validated
predictors of bleeding in this population. If sGPVI is ultimately
validated as a predictor of bleeding in patients with suspected
HIT, it could be used to inform estimation of bleeding risk and
decisions about intensity of anticoagulation.
In summary, we identified sGPVI levels as an independent marker of
bleeding risk among patients with suspected HIT. sGPVI levels
could prove useful in clinical practice as a means of estimating
Table 1. Demographic and clinical characteristics of patients with





(n 5 167) P
Age, median (range), y 65 (19-86) 67 (24-92) .373
Race, n (%) .140
White 72 (80.9) 113 (67.8)
Hispanic 1 (1.1) 2 (1.2)
African American 14 (15.7) 48 (28.7)
Asian 2 (2.3) 4 (2.4)
ICU, n (%) 66 (74.2) 68 (40.7) ,.001
Primary service, n (%) .022
Surgical 56 (62.9) 80 (47.9)
Medical 33 (37.1) 87 (52.1)
Sepsis, n (%)* 37 (41.6) 33 (19.8) ,.001
Platelet count on day of blood
sample collection, median
(range), 3109/L†
54.5 (8-200) 79 (13-422) .0004
Serotonin release assay, n (%) .863
Positive 10 (11.2) 15 (8.9)
Indeterminate 1 (1.1) 1 (0.6)
Negative 77 (86.5) 150 (89.8)
Missing 1 (1.1) 1 (0.6)
PF4/H ELISA OD, n (%) .749
,0.4 63 (70.8) 117 (70.1)
0.4-1.0 7 (7.9) 16 (9.6)
1.0-2.0 7 (7.9) 17 (10.2)
.2.0 12 (13.5) 16 (9.6)
Missing 0 (0) 2 (1.2)
HIT status, n (%) .509
Positive 15 (16.9) 23 (13.8)
Negative 74 (83.5) 144 (86.2)
ELISA, enzyme-linked immunosorbent assay; OP, optical density; PF4/H, platelet factor
4/heparin.
*International Classification of Diseases, Ninth Revision, code for sepsis during admission
that sGPVI was drawn.
†Platelet count on day of blood sample collection (first count of day). Nine patients were
























Figure 2. Distribution of sGPVI levels in patients with and without bleeding
events. Distribution of sGPVI levels in patients with suspected HIT who did and did
not have an ISTH major bleeding event. Blue line indicates median plasma sGPVI
level for each group.
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bleeding risk and guiding empiric treatment in this population,
although prospective validation is needed.
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